Reata Pharmaceuticals Announces Participation in the Barclays Global Healthcare Conference

Rhea-AI Summary

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) announced its participation in the Barclays Global Healthcare Conference from March 14-16 in Miami, Florida. Manmeet Soni, President, COO, and CFO, will engage in a fireside chat at the event. The company is focused on developing innovative therapies for severe diseases and has made significant strides with the first FDA-approved product for Friedreich’s ataxia. Additionally, Reata is advancing its pipeline, including bardoxolone methyl for chronic kidney disease and cemdomespib for diabetic neuropathic pain, although both drugs remain investigational and unproven by regulatory standards.

Positive

• Participation in the Barclays Global Healthcare Conference may enhance visibility and investor interest.
• The company has FDA approval for its product targeting Friedreich’s ataxia, a significant milestone.

Negative

• Bardoxolone and cemdomespib are still investigational and lack established safety and efficacy.
• Future product approvals hinge on uncertain outcomes of clinical trials and regulatory reviews.

PLANO, Texas--(BUSINESS WIRE)-- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that management will participate in the Barclays Global Healthcare Conference held next week, March 14-16, in Miami, Florida. Manmeet Soni, Reata’s President, Chief Operating Officer, and Chief Financial Officer will be participating in a fireside chat during the conference.

About Reata

Reata is a biopharmaceutical company committed to developing and commercializing novel therapeutics for patients with serious or life-threatening diseases with few or no approved therapies. We focus on molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata developed the first and only U.S. Food and Drug Administration approved product for Friedreich’s ataxia. In addition, Reata has a robust pipeline and is developing bardoxolone methyl (“bardoxolone”) for the treatment of patients with various forms of chronic kidney disease and cemdomespib for the treatment of patients with diabetic neuropathic pain. Bardoxolone and cemdomespib are investigational drugs, and their safety and efficacy have not been established by any regulatory agency. For more information visit www.reatapharma.com and follow us on LinkedIn and Twitter.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, our plans and objectives for the commercialization of our products and the timing thereof, our expectations regarding the size of the patient population for our products, and our plans to research, develop, and commercialize our other product candidates. You can identify forward-looking statements because they contain words such as “believes,” “will,” “may,” “aims,” “plans,” “model,” and “expects.” Forward-looking statements are based on Reata’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, (i) the timing, costs, conduct, and outcome of our clinical trials and future preclinical studies and clinical trials, including the timing of the initiation and availability of data from such trials; (ii) the timing and likelihood of regulatory filings and approvals for our product candidates; (iii) whether regulatory authorities determine that additional trials or data are necessary in order to obtain approval (iv) the potential market size and the size of the patient population for our products and the market opportunities for our products; (v) our ability to successfully build our commercial infrastructure to manufacture, market and sell our products, including the successful development and implementation of our sales and marketing campaigns for our products; (vi) the ability of our third-party suppliers and contract manufacturers to manufacture our products at the required quality and quantities and in compliance with applicable laws and regulations; and (vii) other factors set forth in Reata’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, under the caption “Risk Factors.” The forward-looking statements speak only as of the date made and, other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005321/en/

Reata Pharmaceuticals, Inc.

(972) 865-2219

https://www.reatapharma.com/

Investor Relations & Media Relations:

John Hunter ir@reatapharma.com

Wendy Segal media@reatapharma.com

https://www.reatapharma.com/contact-us/

Source: Reata Pharmaceuticals, Inc.

FAQ

When is Reata Pharmaceuticals participating in the Barclays Global Healthcare Conference?

Reata Pharmaceuticals will participate in the Barclays Global Healthcare Conference from March 14-16.

Who from Reata Pharmaceuticals will speak at the Barclays Global Healthcare Conference?

Manmeet Soni, President, COO, and CFO, will participate in a fireside chat.

What is the significance of Reata's FDA-approved product?

Reata developed the first FDA-approved product for Friedreich’s ataxia, marking a significant achievement in rare disease treatment.

What is the status of bardoxolone and cemdomespib?

Both bardoxolone and cemdomespib are investigational drugs, and their safety and efficacy have not yet been established.